Sodium Sulfacetamide NDC 63629-9263

NDC codes

FDA NDC Directory

Product NDC (as listed)63629-9263Labeler and product segments. Claims need a package NDC.

Product NDC at billing width63629-9263Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
63629-9263-1	63629926301	355 g in 1 BOTTLE (63629-9263-1)Marketed from Jan 15, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sodium Sulfacetamide
Generic name (nonproprietary): sodium sulfacetamide
Active ingredients: Sulfacetamide sodium — 100 mg/g
Dosage form: Liquid
Route: Topical
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: Unapproved drug (other)
Marketing start: Jan 15, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Sulfonamides (Chemical structure)
Identifiers: Product ID 63629-9263_fb76cf7a-2f98-48e9-88f6-389b4cf93b1bSPL ID fb76cf7a-2f98-48e9-88f6-389b4cf93b1bSPL set ID c9f90612-32c6-44ba-85d5-82842f0e1ba9RxCUI 1006107UNII 4NRT660KJQ
Pharmacologic class: Sulfonamide Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N463629926301 followed by a unit qualifier and the quantity

Package 63629-9263-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 24, 2026.

Indications (excerpt from the label)

Indications This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)